Training

MetaCore Training

Free on line training showing MetaCore and MapEditor basics using case study examples are available every first Monday of the month.

United States MetaCore training at 10am PDT/1pm EDT

European MetaCore training at 10am GMT/11am CET

To receive invitations please email training@genego.com.

• February 4^th, 2008 - Knowledge mining using GeneGo content
• March 3^rd, 2008 - Discern Disease Networks using GeneGo Pathways and functional processes information
• April 7^th, 2008 - Identify Biomarkers by comparing experiments or gene lists
• May 5^th, 2008 - Functional Enrichment Analysis using different data types
• June 2^nd, 2008 - Build directional or causative networks to reveal disease mechanisms
• July 7^th, 2008 - Reducing data complexity in pathway analysis: from filtering to Boolean queries to strategic network visualizations and layouts
• August 4^th, 2008 - Adding power and unique custom research insight with MetaCore add-on modules
• September 1^st, 2008 - Predicting downstream effects of gene regulation on core metabolism
• October 6^th, 2008 - Genome-wide “power queries” and interactome analysis for target identification and biomarker discovery
• November 3^rd, 2008 - Understand the character of your data set using GeneGo ontologies and optimized filtering
• December 1^st, 2008 - Reducing data complexity in pathway analysis: from filtering to Boolean queries to strategic network visualizations and layouts

MetaDrug Training

Free on line training showing MetaDrug and Tox basics using case study examples are available every last Monday of the month. To receive invitations please email training@genego.com.

• January 28^th, 2008
• February 25^th, 2008
• March 31^st, 2008 - Mechanistic toxicogenomic data interpretation using MetaDrug^TM
• April 28^th, 2008 - Rank and prioritizing lead chemical series using MetaDrug^TM
• May 19^th, 2008 - Comprehensive target assessment using MetaDrug^TM
• June 30^th, 2008 - Mechanistic toxicogenomic data interpretation using MetaDrug^TM
• July 28^th, 2008 - Rank and prioritizing lead chemical series using MetaDrug^TM
• August 25^th, 2008 - Comprehensive target assessment using MetaDrug^TM
• September 29^th, 2008
• October 24^th, 2008
• November 24^th, 2008
• December 29^th, 2008

MetaDiscovery Platform Breast Cancer Case Study Training

MetaDiscovery approach for predicting structure-based effects of compounds and integrating with expression-based data analysis

Gene expression profiling has been of great help in defining molecular cancer phenotypes, which can be used for diagnostic classification or anticipation of treatment outcome. Sorlie et al sought to better define the subpopulations of breast cancer by applying gene clustering analysis to microarray data and correlating them with clinical outcomes.

In order to further define functional biological profiles of patient groups of various patient clusters and hypothesize about the potential group differences in response to anti-cancer treatment, integrative pharmacogenomic pathway analysis methods are needed. Here we use MetaCore (GeneGo Inc.) to report the pathway and network analysis of two of the clusters reported in the study (ERBB2+ and basal), which have the worst survival and metastasis development prognosis. We further use MetaDrug to predict system-level effects of Iressa (gefitinib) and Tarceva (erlotinib) starting with molecular structures of the compounds and elucidating regulatory networks and pathway enrichment based on the respectively predicted targets. This MetaDiscovery approach may provide highly important insights in the process of drug discovery and more targeted treatment of specific classes of breast cancer. To receive invitations please email training@genego.com

• March 21^st, 2008
• April 18^th, 2008
• May 9^th, 2008

MetaDiscovery Platform Training Using MetaCore and MetaDrug

MetaDiscovery approach for predicting structure-based effects of compounds (MetaDrug) and integrating with expression-based data analysis (MetaCore).

Gene expression profiling has been of great help in defining molecular cancer phenotypes, which can be used for diagnostic classification or anticipation of treatment outcome. Expression-based signatures are also used in toxicogenomic studies during drug development and safety assessment.

In order to further define functional biological profiles of patient groups or of various compound-effect-specific clusters, integrative pharmacogenomic pathway analysis methods are needed. Here we use MetaCore to report the pathway and network analysis of Omics data, and further, we use MetaDrug to predict system-level drug effects based on molecular structures of the compounds alone. This allows us to elucidate regulatory networks and pathway enrichment based on the respectively predicted targets for structures of interest and related back to the Omics data by overlaying study results on compound-based networks.

Such integrative MetaDiscovery approach may provide highly important insights in the process of drug discovery and more targeted treatment development of specific clinical classes for various diseases.

• June 13^th, 2008
• July 11^th, 2008
• August 8^th, 2008
• September 12^th, 2008
• October 10^th, 2008
• November 14^th, 2008
• December 12^th, 2008

On site training is available for $2,000 per day plus expenses.

Please contact training@genego.com to schedule dates.